Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
Synthetic Biologics, Inc. (NYSE American: SYN) announces its participation in the virtual B. Riley Securities Oncology Conference on January 27-28, 2022. CEO Steven Shallcross and other key management will present on January 28 at 2:30 PM ET. The presentation will be accessible live and a replay will be available on the company's website post-event. Synthetic Biologics focuses on developing therapeutics for unmet medical needs and recently agreed to acquire VCN Biosciences, which specializes in oncolytic adenoviruses aimed at treating tumors. More details can be found on their website.
- None.
- None.
ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the B. Riley Securities Oncology Conference being held virtually on January 27-28, 2022.
Steven Shallcross, Chief Executive Officer and Chief Financial Officer of Synthetic Biologics, Manel Cascalló, PhD, Chief Executive Officer of VCN, and other key members of Company management are scheduled to present on Friday, January 28, 2022 at 2:30 PM Eastern Time. The live presentation will be available at https://www.webcaster4.com/Webcast/Page/2828/44457 and a replay of the presentation will be publicly available under the "News/Events" section of the Synthetic website at https://ir.syntheticbiologics.com/ir-calendar.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company recently announced it has entered into a definitive agreement to acquire VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) delivery to trigger tumor cell death and promote immune cell infiltration into tumors. The transaction is expected to close during the first quarter of 2022, and is subject to, among other things, the approval by the Spanish government of the Company's acquisition of VCN under Spain's Foreign Investment Act and other customary closing conditions. In addition, the Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-b-riley-securities-oncology-conference-on-january-28-2022-301469051.html
SOURCE Synthetic Biologics, Inc.
FAQ
What is the date of Synthetic Biologics' presentation at the B. Riley Securities Oncology Conference?
Where can I watch the Synthetic Biologics presentation?
What recent acquisition did Synthetic Biologics announce?
What are the lead candidates of Synthetic Biologics?
How can I access the replay of Synthetic Biologics' presentation?
